BenevolentAI Investor Conference Presentation Deck

BEN-2293 - indicative data from Phase Ib Caveats: • Phase lb was NOT powered to meaningfully assess efficacy - only 6 patients dosed with active per group • Maximum duration of dosing 14 days (EASI score changes typically measured at 28 days) Mean change from baseline Mean Change from Baseline %BSA affected in treated areas 14 day placebo treatment 1 0 -4 -5 -6 0 Cohort 3 Patients dosed 1% ointment, 30% BSA, once per day 1 2 3 Cohort 4 Patients dosed 1% ointment, 30% BSA, twice per day 4 EASI: Eczema Area and Severity Index 5 6 7 Day 8 9 10 11 12 13 14 15 0.25% QD 10%BSA 7d 1% QD 10%BSA 7d 1% QD 30%BSA 14d 1% BID 30%BSA 14d PBO 7d PBO 14 d Benevolent 20

View entire presentation